期刊文献+

染色体1p/19q杂合性缺失在鉴别脑胶质肿瘤组织学类型中的意义 被引量:3

下载PDF
导出
摘要 目的探讨染色体1p/19q杂合性缺失在鉴别脑胶质肿瘤组织学类型中的意义。方法采用荧光免疫原位杂交技术检测104例脑胶质肿瘤1p/19q杂合性缺失情况,并随访观察预后。结果 1p/19q杂合性缺失70例,其中少突胶质细胞肿瘤54例,星形细胞瘤16例。少突胶质细胞瘤染色体1p、19q、1p/19q联合缺失的发生率分别为61.6%、67.1%、54.8%,星形细胞瘤分别为38.7%、29.0%、16.1%,两组数据差异有统计学意义(P<0.01)。少突胶质细胞瘤染色体1p、19q、1p/19q联合缺失的发生率分别为63.2%(24/38)、63.2%(24/38)、52.6%(20/38),间变性少突胶质细胞瘤分别为58.8%(10/17)、64.7%(11/17)、52.9%(9/17),不同级别的少突胶质细胞瘤的染色体缺失差异无统计学意义(P>0.05)。有1p/19q杂合性缺失的少突胶质细胞肿瘤患者中位生存时间为74个月,大于未缺失者(39个月),两者差异有统计学意义(P<0.05)。结论染色体1p/19q杂合性缺失对鉴别少突胶质细胞肿瘤与星形细胞瘤可能有一定帮助,且对临床治疗及预后判断有一定的指导作用。
出处 《广东医学》 CAS CSCD 北大核心 2014年第5期684-686,共3页 Guangdong Medical Journal
基金 江西省教育厅科学技术研究项目(编号:GJJ10015) 江西省科技支撑项目(编号:2009BSB11206)
  • 相关文献

参考文献10

  • 1KLEIHUS P, OHGAK.I H. Phenotype vs genotype in the evolution of astrocytic brain tumors[J]. Toxicol Pathol, 2000, 28( I ) : 164 - 170.
  • 2LOUIS D N, OHGAKI H, WIESTLER O D, et al. World health organizaon classification of turnouts of the central nervous system [ M]. Lyon: IARC Press, 2007.
  • 3CAIRNROSS J G, MACDONALD D R. Successful chemotherapy for recurrent malignant oligodendroglioma[ J]. Ann Neurol, 1988, 23(4) : 360-364.
  • 4FELSBERG J, ERKWOH A, SAHEL M C, et al. Oligodendrogli- al tumors refinement of candidate regions on chromosome arm 1 p and correlation of 1 p/19q atatus with survival [ J ]. Brain Pathol, 2004, 14(2) : 121 -130.
  • 5TEWS B, FELSBERG l, HARTMANN C, et al. Identification of novel oligodendroglioma - associated candidate tumor suppressor genes in lp36 and 19q13 using microarray- based expression pro- filing[ J ]. Cancer, 2006, 119 (4) : 792 - 800.
  • 6LI K K, PANG J C, CHUNG N Y, et al. EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome alms lp and 19q[J]. Cancer, 2007, 120(4) : 947 -950.
  • 7KITANGE G, MISRA A, LAW M, et al. Chromosom',d imbal- ances detected by array comparative genomic hybridization in hu- man ofigodendrogliomas and mixed oligoastrocytomas [ J ]. Genes Chromosomes Cancer, 2005,42 (1) : 68 -77.
  • 8GELPI E, AMBROS I M, BIRNER P, et al. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for lp and 19q LOH analysis in paraffin -embedded oligodendroglial tumor specimens[J]. Mod Pathol, 2003, 16(7) : 708 -715.
  • 9熊佶,刘颖,李超,朱静静,叶诸榕,毛颖,汪寅.少突胶质细胞瘤染色体1p/19q杂合性缺失与p53蛋白表达的相关性研究[J].中华病理学杂志,2009,38(7):445-450. 被引量:10
  • 10李俊芝,侯国胜,蒋茂芬,张巍.1p/19q分子遗传学改变在少突胶质细胞瘤和星形细胞瘤鉴别诊断中意义[J].中华实用诊断与治疗杂志,2011,25(8):772-774. 被引量:3

二级参考文献33

  • 1高丽,董子明.基因突变与人类脑胶质瘤的关系及诊治进展[J].实用诊断与治疗杂志,2005,19(2):117-120. 被引量:5
  • 2步星耀,赵红卫,张云龙,王勇,秦玉花.脑胶质瘤患者手术前后免疫功能的改变[J].实用诊断与治疗杂志,2005,19(5):340-341. 被引量:2
  • 3何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 4张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 5van den Bent MJ,Carpentier AF,Bmndes AA,et al.Adjuvant procarbazine,lomustine,and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendregliomas and oligoastrecytomas:a randomized European Organisation for Research and Treatment of Cancer phase Ⅲ trial.J Clin Oncol,2006,24(18):2715-2722.
  • 6Ino Y,Zlateseu MC,Sazaki H,et al.Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss.J Neurosurg,2000,92(6):983-990.
  • 7Louis DN,Ohgaki H,Wiestler OD,et al.WHO classification of tumours of the central nervous system.Lyon:IARC Press,2007.
  • 8Caimcross G,Macdonald D,Ludwin S,et al.Chemotherapy for anaplastic oligodendroglioma.National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,1994,12(10):2013-2021.
  • 9Leighton C,Fisher B,Bauman G,et al.Supratentorial low-grade glioma in adults:an analysis of prognostic factors and timing of radiation.J Clin Oncol,1997,15(4):1294-1301.
  • 10Smith JS,Perry A,Borell TJ,et al.Alterations of chromosome arm8 1p and 19q as predictem of survival in oligedendrogliomas,astrecytomas,and mixed oligcastrocytomas.J Clin Oncol,2000,18(3):636-645.

共引文献11

同被引文献32

  • 1潘婷,苏春秋,张璇,鲁珊珊,施海彬,洪汛宁.常规MRI特征在预测弥漫性低级别胶质瘤1p/19q缺失状态的应用价值[J].临床放射学杂志,2020,39(6):1189-1194. 被引量:14
  • 2何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量:10
  • 3张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量:9
  • 4Bourne TD,Schiff D.Update on molecular findings,management and outcome in low-grade gliomas[J].Nat Rev Neurol,2010,6(12):695-701.
  • 5Hofer S,Lassman AB.Molecular markers in gliomas:impact for the clinician[J].Target Onco1,2010,5(3):201-210.
  • 6Reifenberger G,Louis DN.Oligodendroglioma:toward molecular definitions in diagnostic neuron-oncology[J].J Neuropathol Exp Neurol,2003,62(2):111-126.
  • 7Smith JS,Perry A,Borell TJ,et al.Alterations of chromosome amislp and 19q as predictors of survival in oligodendrogliomas,astrocytomas,and mixed oligoastrocytomas[J].J Clin Oncol,2000,18(3):636-645.
  • 8Chinot O.Chemotherapy for the treatment of oligodendroglial tumors[J].Semin Oncol,2001,28(4 suppl 13):13-18.
  • 9Van den Bent MJ.New perspectives for the diagnosis and treatment of oligodendroglioma[J].Expcrt Rev Anticancer Ther,2001,1(3):348-356.
  • 10Huang L,Jiang T,Yuan F,et al.Correlation of chromosome lp and l9q status and expression of MGMT,p53 and Ki-67 in diffuse gliomas of WHO grade Ⅱ and Ⅲ:a clinicopathological study[J].Neuropathol Appl Neurobiol,2009,35(4):367-379.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部